Celltrion plans to launch a biosimilar each year for next decadeThere are plenty of pharma companies outlining their strategies for the new decade this week at the JP Share XCelltrion plans to launch a biosimilar each year for next decadehttps://pharmaphorum.com/news/celltrion-plans-to-launch-a-biosimilar-each-year-for-next-decade/
Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from BayerThe UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the Share XTumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayerhttps://pharmaphorum.com/news/tumour-agnostic-drugs-game-changing-says-nice-as-it-rejects-one-from-bayer/
Nektar pulls pain drug after bruising FDA panel meetingNektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory Share XNektar pulls pain drug after bruising FDA panel meetinghttps://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/
NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCCNICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia Share XNICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCChttps://pharmaphorum.com/news/nice-rejects-astellas-xospata/
Roche and Illumina forge genomics alliance for cancer testingRoche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, Share XRoche and Illumina forge genomics alliance for cancer testinghttps://pharmaphorum.com/news/roche-and-illumina-forge-genomics-alliance-for-cancer-testing/
Novartis strikes landmark deal with NHS to speed up inclisiran accessNovartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran Share XNovartis strikes landmark deal with NHS to speed up inclisiran accesshttps://pharmaphorum.com/news/novartis-strikes-landmark-deal-with-nhs-to-speed-up-inclisiran-access/
NICE backs Medtronic’s AF monitor in post-stroke patientsEngland’s NHS could prevent hundreds of strokes of unknown cause with a new implantable monitor that transmits data Share XNICE backs Medtronic’s AF monitor in post-stroke patientshttps://pharmaphorum.com/news/nice-backs-medtronics-af-monitor-in-post-stroke-patients/
ViiV files first-in-class HIV drug in EuropeViiV Healthcare has filed its new HIV drug fostemsavir for approval in Europe, a few weeks after the Share XViiV files first-in-class HIV drug in Europehttps://pharmaphorum.com/news/viiv-files-first-in-class-hiv-drug-in-europe/
Akcea’s rare disease drug Waylivra way too pricey for NHS, says NICELess than a week into 2020 and NICE has provisionally ruled against NHS funding for another drug – Share XAkcea’s rare disease drug Waylivra way too pricey for NHS, says NICEhttps://pharmaphorum.com/news-market-access/akceas-rare-disease-drug-waylivra-way-too-pricey-for-nhs-says-nice/
NICE rejects Roche’s Tecentriq in new lung cancer useNICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a Share XNICE rejects Roche’s Tecentriq in new lung cancer usehttps://pharmaphorum.com/news/nice-rejects-roches-tecentriq-in-new-lung-cancer-use/
FDA clears Eisai’s insomnia drug DayvigoThe FDA’s traditional last-minute flurry of approvals as the year heads to a close included Eisai’s Dayvigo, a Share XFDA clears Eisai’s insomnia drug Dayvigohttps://pharmaphorum.com/news/fda-clears-eisais-insomnia-drug-dayvigo/
EMA counts the cost of Brexit in lost staff and narrower workloadThe EMA’s forced move from London to Amsterdam in the wake of the UK’s decision to leave the Share XEMA counts the cost of Brexit in lost staff and narrower workloadhttps://pharmaphorum.com/news/ema-counts-the-cost-of-brexit-in-lost-staff-and-narrower-workload/
Intra-Cellular ends year with OK for schizophrenia drug lumateperoneUS biotech Intra-Cellular Therapies’ has claimed an FDA approval for schizophrenia therapy lumateperone setting up the launch of Share XIntra-Cellular ends year with OK for schizophrenia drug lumateperonehttps://pharmaphorum.com/news/intra-cellular-ends-year-with-ok-for-schizophrenia-drug-lumateperone/
FDA knocks back ViiV, J&J’s long-acting HIV regimenPeople with HIV hoping to be freed from daily doses of tablets will have to wait a little Share XFDA knocks back ViiV, J&J’s long-acting HIV regimenhttps://pharmaphorum.com/news/fda-knocks-back-viiv-jjs-long-acting-hiv-regimen/
Novartis sets up free lottery for $2.1m SMA drug outside USNovartis is planning to give away 100 doses of its hugely expensive spinal muscular atrophy gene therapy Zolgensma Share XNovartis sets up free lottery for $2.1m SMA drug outside UShttps://pharmaphorum.com/news/novartis-to-give-away/
Amgen, Allergan join Rituxan biosimilar challenge with FDA filingAmgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the Share XAmgen, Allergan join Rituxan biosimilar challenge with FDA filinghttps://pharmaphorum.com/news/amgen-allergan-join-rituxan-biosimilar-challenge-with-fda-filing/
Merck claims first-ever FDA approval for an Ebola vaccineMerck & Co’s Ebola vaccine Ervebo has been cleared for marketing in the US, just weeks after getting Share XMerck claims first-ever FDA approval for an Ebola vaccinehttps://pharmaphorum.com/news/merck-claims-first-ever-fda-approval-for-an-ebola-vaccine/
Trump proposes drug import plan to cut prices, ahead of impeachmentOne of the last acts by the Trump administration before the House voted in favour of impeaching the Share XTrump proposes drug import plan to cut prices, ahead of impeachmenthttps://pharmaphorum.com/news/trump-proposes-drug-import-plan-to-cut-prices-ahead-of-impeachment/
